25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
  • Patent number: 10654915
    Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: May 19, 2020
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
  • Patent number: 10617736
    Abstract: This invention relates to a method of increasing energy available to skeletal muscle cells comprising administering to the cells an effective amount of Tenurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP to enhance muscle performance or recovery after injury as well as to prevent and/or treat a number of conditions including insulin resistance, type II diabetes, hypoxia and glycogen storage diseases.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: April 14, 2020
    Inventors: Yani Chen, David Lovejoy
  • Patent number: 10596265
    Abstract: A nanogel comprising a self-organizing peptide, a chitosan and polyethylene glycol is described.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: March 24, 2020
    Assignees: 3-D Matrix, Ltd., Tokyo University of Science Foundation
    Inventors: Hidenori Otsuka, Daisuke Matsukuma
  • Patent number: 10548945
    Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: February 4, 2020
    Assignee: AFFILOGIC
    Inventor: Olivier Kitten
  • Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
  • Patent number: 10533039
    Abstract: The present invention provides peptides comprising a sequence of X?6X?5X?4X?3X?2X?1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26 YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: January 14, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, John Hanney McGee
  • Patent number: 10532040
    Abstract: The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: January 14, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Ann M. Bode, Young-Yeon Cho, Zigang Dong, Dong Joon Kim
  • Patent number: 10533044
    Abstract: Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis. Also provided herein is a crystal comprising ?v?3 ectodomain complexed with inhibitor knottin 2.5 F. Further provided herein is a crystal comprising ?V?3 ectodomain complexed with inhibitor hFN10. In another aspect, the invention features a method that includes using a three-dimensional model of a complex that includes an integrin ectodomain.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: January 14, 2020
    Assignee: The General Hospital Corporation
    Inventor: M. Amin Arnaout
  • Patent number: 10501498
    Abstract: Provided is a new conotoxin peptide ?-CPTx-bt101. The conotoxin peptide ?-CPTx-bt101 has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1, or has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1 and that is formed after substitution, addition or deletion of one or more amino acids are performed and has original functions. Also provided is polynucleotide for coding the peptide, comprising a constructed body of the polynucleotide, an expression carrier and transformed cells. A peptide preparation method and uses in the treatment of diseases related to a calcium ion channel.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: December 10, 2019
    Assignee: BGI SHENZHEN
    Inventors: Jie Liu, Zhilong Lin, Bo Wen, Ting Tong, Fen Mo, Chao Peng, Qiong Shi
  • Patent number: 10478524
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 19, 2019
    Assignee: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo G. Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • Patent number: 10471163
    Abstract: Provided herein are methods for determining the presence or absence of active thrombus formation using a linear polypeptide that binds fibrin upon cyclization. Also provided are compounds comprising linear polypeptide probes that are cyclized in the presence of protein disulfide isomerase.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: November 12, 2019
    Assignee: The General Hospital Corporation
    Inventors: Galen Loving, Peter D. Caravan
  • Patent number: 10470461
    Abstract: Disclosed are hypersensitive-response eliciting peptides that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: November 12, 2019
    Assignee: Plant Health Care, Inc.
    Inventors: Zhongmin Wei, Gregory A. Zornetzer, Stephen Bornick
  • Patent number: 10472389
    Abstract: The present invention provides methods for increasing purity of an Fc-containing protein by removing protein aggregates during the Protein A chromatography step used during the purification of the Fc-containing protein.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 12, 2019
    Assignee: EMD Millipore Corporation
    Inventors: Nanying Bian, Melissa Holstein
  • Patent number: 10472401
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 12, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10464978
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10358469
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to a polypeptide comprising or consisting of i) an amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, ii) an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1, or iii) an amino acid sequence which is a retro-inverso of the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, iv) an amino acid sequence which is retro-inverso of the amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: July 23, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)
    Inventors: Jean-Luc Poyet, Heriberto Bruzzoni-Giovanelli, Léonard Jagot-Lacoussiere
  • Patent number: 10323070
    Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 18, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Steven J. Norris
  • Patent number: 10308693
    Abstract: The invention provides a peptide comprising: a core amino acid sequence, which is identical or similar to the amino acid sequence of a member of the Cecropin family. The invention further provides a nucleic acid sequence encoding the peptide and a vector comprising said nucleic acid. The invention further provides a pharmaceutical composition comprising said peptide or said nucleic acid. The invention further provides methods of treating an infection, overcoming inherent or acquired resistance of a microorganism to an antibiotic agent or disinfecting a wound, the methods comprises administering the peptide to a subject in need thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: June 4, 2019
    Assignee: OMNIX MEDICAL LTD.
    Inventors: Niv Bachnoff, Moshe Cohen-Kutner
  • Patent number: 10273290
    Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating the viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: April 30, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Loren D. Walensky, Gregory Bird
  • Patent number: 10261082
    Abstract: The invention provides for a method for the detection of FeLV infection in a patient, wherein a sample obtained from the patient is contacted in-vitro with a recombinant transmembrane p15E protein in a p15 (E) antibody binding step.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: April 16, 2019
    Assignee: UNIVERSITAT ZURICH
    Inventors: Hans Lutz, Eva Bonzli, Regina Hofmann-Lehmann
  • Patent number: 10259850
    Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: April 16, 2019
    Assignee: MEDPACTO INC.
    Inventors: Il Ho Ha, Seok Ho Yoo, Hye Nan Kim, Yeung Chul Kim, Ju Ry Lim
  • Patent number: 10238757
    Abstract: A molecular probe for use in detection of cancer cells expressing an Ig superfamily cell adhesion molecule that binds in a homophilic fashion in a subject includes a targeting agent that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of the Ig superfamily cell adhesion molecule.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 26, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Susann Brady-Kalnay
  • Patent number: 10221216
    Abstract: Described herein are recognition modules that bind specifically to a template nucleic acid and which ligate together in a reducing environment to produce a gamma peptide nucleic acid (?PNA) oligomer. Also provided are methods of synthesizing a ?PNA oligomer on a template using the recognition modules.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: March 5, 2019
    Assignee: Carnegie Mellon University
    Inventors: Danith H. Ly, Raman Bahal, Arunava Manna, Dinesh Chandra Bhunia, Rapireddy Srinivas, Yidan Cong
  • Patent number: 10213486
    Abstract: A formulation of a diluted amino acid fragment is prepared by mixing an amino acid fragment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid fragment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: February 26, 2019
    Assignee: Deseret Biologicals, Inc.
    Inventors: Jacob L. Carter, Edwin Douglas Lephart
  • Patent number: 10183986
    Abstract: A collagen scaffold domain, including a collagenous or collagen-like domain, which directs self-trimerization is provided. The collagen scaffold domain can be fused to one or more heterologous domains, such as an antibody domain. Methods for generating and using the scaffold domains and fusion proteins are also provided.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: January 22, 2019
    Assignee: Industrial Technology Research Institute
    Inventors: Min-Yuan Chou, Chia-Yu Fan, Chuan-Chuan Huang, Hsiu-Chuan Li
  • Patent number: 10155804
    Abstract: To provide a differentiation-inducing composition and a method for producing the differentiation-inducing composition, the present disclosure describes use of a degradation product containing at least a portion of the triple helical domain of collagen or atelocollagen.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: December 18, 2018
    Assignee: Kinki University
    Inventors: Koichi Morimoto, Saori Kunii, Ei Yamamoto, Hiroyuki Ito, Yoshinori Kuboki
  • Patent number: 10130692
    Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: November 20, 2018
    Assignee: Qu Biologics Inc.
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Patent number: 10010614
    Abstract: The invention relates to derivatives of GLP-1 like peptides which are C-terminally extended analogs of native GLP-1. The derivatives comprise two side chains, one at a position corresponding to position 42, and one at a position corresponding to position 18, 23, 27, 31, 36, or 38, wherein both positions are when compared to GLP-1(7-37). The side chains comprise a C19, C20, or C22 diacid protracting moiety and optionally a linker. The invention also relates to intermediate products in the form of novel GLP-1 analogs incorporated in the derivatives of the invention, as well as pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 3, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Steffen Reedtz-Runge, Jacob Kofoed
  • Patent number: 10005822
    Abstract: A system, including methods and compositions, for treatment of ischemia.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 26, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Roger P. Simon, Zhi-Gang Xiong
  • Patent number: 9999694
    Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 19, 2018
    Assignees: Sloan-Kettering Institute for Cancer Research, Cornell University
    Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
  • Patent number: 9975932
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 9969969
    Abstract: A process for producing plasmid DNA E. coli cells comprises a pre-culture and fed-batch process. The culture media of the batch phase and the culture medium added during the feeding phase are chemically defined. The culture medium of the feeding phase contains a growth-limiting substrate and is added, for at least a fraction of the feeding phase, at a feeding rate that follows a pre-defined exponential function, thereby controlling the specific growth rate at a pre-defined value. The process results in high yield and homogeneity of plasmid DNA.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: May 15, 2018
    Assignee: BOEHRINGER INGELHEIM RCV GMBH & CO KG
    Inventors: Hans Huber, Gerhard Weigl, Wolfgang Buchinger
  • Patent number: 9920356
    Abstract: An object of the invention is to provide a nucleic acid detection method which takes advantage of the high specificity of hybridization techniques, reduces the time length and the number of steps required for detection of PCR products, and allows for easy and highly accurate detection by visual observation without the need of special equipment; and a nucleic acid detection device or kit. The invention provides a method for detecting a target nucleic acid in a sample, which includes performing amplification of the target nucleic acid sequence to synthesize an amplification product having a partially double-stranded structure where a single-stranded region is added to each end of the target sequence, and hybridizing a nucleic acid sequence bound to a development medium and a nucleic acid sequence labeled with a labeling compound with the single-stranded regions of the amplification product to form a sandwich hybridization complex; and a detection device thereof.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: March 20, 2018
    Assignee: KANEKA CORPORATION
    Inventors: Koji Takahashi, Shigehiko Miyamoto, Takaaki Jikihara, Jun Tomono
  • Patent number: 9913878
    Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: March 13, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Richard H. Kimura, Aron M. Levin
  • Patent number: 9879071
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 30, 2018
    Assignee: Prothena Biosciences Limited
    Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
  • Patent number: 9879327
    Abstract: Methods and compositions for detecting, identifying, and quantifying Brassica A genomic DNA are described. The methods are specific to the Brassica A genome and do not cross-react with other Brassica species, crops or weedy relatives that could contribute to contamination of a canola field.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: January 30, 2018
    Assignee: E. I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Matthew Curtis Harmon, Nancy L Henderson, Cathy Xiaoyan Zhong
  • Patent number: 9872825
    Abstract: An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: January 23, 2018
    Assignee: Osaka University
    Inventors: Hironori Nakagami, Ryuichi Morishita, Hideki Tomioka, Akiko Tenma
  • Patent number: 9872919
    Abstract: The present invention provides a compound having the structure: wherein X is a therapeutic agent containing at least one amine nitrogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon ?; Z is CH3 or CF3; R1 is —H, —NR2R3, —NH—C(?O)—R4, —NH—C(?O)—OR4, —CH2—C(?O)—NR5R6, —OR7, —CO2R7, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, or heteroaryl, wherein R2, R3, R4, R5, R6 and R7 are each, independently, —H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 23, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Nobuhide Ueki, Michael J. Hayman
  • Patent number: 9862837
    Abstract: The invention provided herein presents a novel family of antifouling agents based on hydroxylated and fluorinated compounds.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: January 9, 2018
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventor: Meital Reches
  • Patent number: 9855312
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 2, 2018
    Assignees: UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
  • Patent number: 9783610
    Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 10, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Chunsheng Li
  • Patent number: 9758548
    Abstract: A method of treating a bacterial infection in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide being between 3 and 5 amino acids, wherein at least one amino acid of the 3 and 5 amino acids is selected from the group consisting of tryptophan, cysteine, proline and methionine.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: September 12, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Noam Adir, Sharon Navon, Tali Swartzmann
  • Patent number: 9717775
    Abstract: The present invention relates to the use of compounds that block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the ?9?10 subtype of the nAChR.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: August 1, 2017
    Assignee: University of Utah Research Foundation
    Inventors: J. Michael McIntosh, Baldomero M. Olivera, Michael A. Ellison, Michelle Vincler
  • Patent number: 9700598
    Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 11, 2017
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
  • Patent number: 9688742
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: June 27, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITE PARIS DIDEROT—Paris 7
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Patent number: 9676823
    Abstract: A polypeptide with a predominantly hydrophobic sequence long enough to span a membrane lipid bilayer as a transmembrane helix (TM) and comprising one or more dissociable groups inserts across a membrane spontaneously in a pH-dependant fashion placing one terminus inside cell. The polypeptide conjugated with various functional moieties delivers and accumulates them at cell membrane with low extracellular pH. The functional moiety conjugated with polypeptide terminus placed inside cell are translocated through the cell membrane in cytosol. The peptide and its variants or non-peptide analogs can be used to deliver therapeutic, prophylactic, diagnostic, imaging, gene regulation, cell regulation, or immunologic agents to or inside of cells in vitro or in vivo in tissue at low extracellular pH.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: June 13, 2017
    Assignees: Rhode Island Council on Postsecondary Education (statutory successor to Board of Governors for Higher Education, State of Rhode Island and Providence Plantations), Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Ursula Lehnert, Donald M. Engelman
  • Patent number: 9670250
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: June 6, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Doron C. Greenbaum
  • Patent number: 9670254
    Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 6, 2017
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Steven J. Norris
  • Patent number: 9670497
    Abstract: The invention is directed to synthetic promoter constructs for enhanced transgene expression in plants and to expression cassettes comprising the synthetic promoter constructs. The expression cassettes may include various elements for improved expression, stability of the expressed protein or efficient purification of the expressed protein, including signal sequences, protease cleavage sites for release of the target protein, trafficking peptides for trafficking of the expressed protein to various plant compartments, and/or various tags. The invention further relates to methods of expression of transgenic proteins in plants with the use of the synthetic promoter constructs and expression cassettes.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: June 6, 2017
    Assignee: AZARGEN BIOTECHNOLOGIES (PTY) LTD.
    Inventors: Mauritz Venter, Jacobus Petrus Zwiegelaar
  • Patent number: 9655377
    Abstract: The present invention relates to plants with increased levels of water soluble carbohydrates, particularly fructan, in the stem and leaf sheath. The present invention also provides methods of identifying and/or producing these plants. In particular, the present invention relates to a novel class of polypeptides designated MYB13 which upregulate the expression of enzymes involved in fructan synthesis. The present invention further relates to a novel promoter element that can be used to express genes predominantly in the stem and leaf sheath during the early reproductive stage of a plant.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: May 23, 2017
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Gangping Xue, Cathrine Lynne Mcintyre, Maarten Christiaan Kooiker